BCIQ Profiles

Company Profile ReportTarget Profile Report

Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout

Pivotal data for rilonacept in recurrent pericarditis put Kiniksa on track to bring its first program to market and gain rights from Regeneron to additional indications.

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares rose $2.97 (13%) to $26 Monday, adding

Read the full 382 word article

How to gain access

Continue reading with a
two-week free trial.